Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
15 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 9 with minor changes only.
- Minor: Nivolumab With or Without Stereotactic Radiosurgery · Recurrent, Advanced, or Metastatic Chordoma Trial completed
- Notable: TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Results posted: Nov 6, 2026
- Notable: Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer Results posted: Nov 4, 2026
- Minor: KIEO · Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN) Primary completion pushed from Oct 16, 2026 to Dec 2026
- Minor: Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection Enrollment increased: 150 → 200 participants
- Notable: Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC) Start date pushed from Oct 1, 2026 to Dec 1, 2026
- Notable: Nivolumab With or Without Relatlimab · Potentially Resectable Hepatocellular Carcinoma Results posted: Oct 28, 2026
- Notable: IRIS · Sarilumab With Immune Checkpoint Inhibitor Rechallenge · Clinically Significant Immune Related Adverse Events Start date pushed from Oct 2026 to Dec 2026
- Minor: Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer Enrollment closed, study ongoing
- Minor: Allogeneic HPV-specific T Cells · Recurrent or Metastatic HPV16+ Cancers Primary and study completion pushed from Oct 1, 2026 to Dec 1, 2026
- Minor: GLAD-KE · GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma Primary completion pushed from Oct 15, 2029 to Nov 15, 2029
- Minor: DRP-104 (Glutamine Antagonist) in Combination With Durvalumab · Advanced Stage Fibrolamellar Carcinoma (FLC) Enrollment closed, study ongoing
- Minor: Blinatumomab · Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Primary and study completion pushed from Oct 30, 2026 to Dec 30, 2026
- Notable: Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme Primary completion pushed from Aug 2026 to Apr 2027
- Minor: Pertuzumab and Trastuzumab as Neoadjuvant Treatment · HER2-Positive Breast Cancer Study completion pushed from Jun 2027 to Dec 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Early Phase 1 | 5 | |
| Phase 1 | 20 | |
| Phase 1/2 | 7 | |
| Phase 2 | 47 |
Not charted: 31 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 33
Prostate Cancer (19) · Breast Cancer (11) · Bladder Cancer (8) · Pancreatic Cancer (8) · Glioblastoma (6) · Glioma (6) · Head & Neck Cancer (6) · Sarcoma (6) · Colorectal Cancer (5) · Leukemia (5)
Get alerts when Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.